Clinical Trial: NCT05261399
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-08-06 |
Study Overview
Brief Summary
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Official Title
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
Conditions
Carcinoma, Non-Small-Cell Lung
Intervention / Treatment
- Drug: Savolitinib
- Drug: Osimertinib
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
Other Study ID Numbers
- D5087C00001
- 2024-511169-12-00
- 2021-006374-24
Start Date (Actual)
2022-08-03
Primary Completion Date (Actual)
2026-07-06
Study Completion Date (Estimated)
2026-11-23
Enrollment (Actual)
341
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-08-06 |
Study Overview
Brief Summary
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Official Title
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
Conditions
Carcinoma, Non-Small-Cell Lung
Intervention / Treatment
- Drug: Savolitinib
- Drug: Osimertinib
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
Other Study ID Numbers
- D5087C00001
- 2024-511169-12-00
- 2021-006374-24
Start Date (Actual)
2022-08-03
Primary Completion Date (Actual)
2026-07-06
Study Completion Date (Estimated)
2026-11-23
Enrollment (Actual)
341
Study Type
Interventional
Phase
Phase 3